![]() |
Name |
asperthrin E
|
Molecular Formula | C28H31N3O6 | |
IUPAC Name* |
(7',7',10,10-tetramethyl-2,2',14-trioxospiro[3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane-11,3'-1H-pyrano[2,3-g]indole]-12-yl)acetate
|
|
SMILES |
CC(=O)OC1C23NC(=O)C4(CCCN4C2=O)CC3C(C)(C)C12C(=O)Nc1c2ccc2c1C=CC(C)(C)O2
|
|
InChI |
InChI=1S/C28H31N3O6/c1-14(32)36-20-27(16-7-8-17-15(19(16)29-22(27)34)9-11-24(2,3)37-17)25(4,5)18-13-26-10-6-12-31(26)23(35)28(18,20)30-21(26)33/h7-9,11,18,20H,6,10,12-13H2,1-5H3,(H,29,34)(H,30,33)/t18-,20-,26-,27-,28?/m0/s1
|
|
InChIKey |
PMWRUYDROIRHHZ-KEKOVESBSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 505.57 | ALogp: | 2.3 |
HBD: | 2 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 114.0 | Aromatic Rings: | 8 |
Heavy Atoms: | 37 | QED Weighted: | 0.567 |
Caco-2 Permeability: | -5.21 | MDCK Permeability: | 0.00002220 |
Pgp-inhibitor: | 0.996 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.238 | 20% Bioavailability (F20%): | 0.827 |
30% Bioavailability (F30%): | 0.64 |
Blood-Brain-Barrier Penetration (BBB): | 0.147 | Plasma Protein Binding (PPB): | 85.45% |
Volume Distribution (VD): | 0.928 | Fu: | 21.29% |
CYP1A2-inhibitor: | 0.006 | CYP1A2-substrate: | 0.485 |
CYP2C19-inhibitor: | 0.217 | CYP2C19-substrate: | 0.936 |
CYP2C9-inhibitor: | 0.564 | CYP2C9-substrate: | 0.577 |
CYP2D6-inhibitor: | 0.112 | CYP2D6-substrate: | 0.141 |
CYP3A4-inhibitor: | 0.883 | CYP3A4-substrate: | 0.934 |
Clearance (CL): | 2.695 | Half-life (T1/2): | 0.067 |
hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.442 |
Drug-inuced Liver Injury (DILI): | 0.904 | AMES Toxicity: | 0.323 |
Rat Oral Acute Toxicity: | 0.899 | Maximum Recommended Daily Dose: | 0.885 |
Skin Sensitization: | 0.02 | Carcinogencity: | 0.97 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.003 |
Respiratory Toxicity: | 0.206 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004071 | ![]() |
0.877 | D03ZZK | ![]() |
0.233 | ||
ENC002052 | ![]() |
0.815 | D06HBQ | ![]() |
0.228 | ||
ENC004072 | ![]() |
0.701 | D09QVV | ![]() |
0.222 | ||
ENC002536 | ![]() |
0.687 | D0T6WT | ![]() |
0.219 | ||
ENC002534 | ![]() |
0.687 | D0W9MM | ![]() |
0.219 | ||
ENC002366 | ![]() |
0.687 | D01HTL | ![]() |
0.219 | ||
ENC002538 | ![]() |
0.664 | D09WYX | ![]() |
0.218 | ||
ENC004945 | ![]() |
0.621 | D06XHC | ![]() |
0.217 | ||
ENC004944 | ![]() |
0.621 | D0P0HT | ![]() |
0.217 | ||
ENC004948 | ![]() |
0.577 | D0OT9S | ![]() |
0.215 |